BRCA testing by single-molecule molecular inversion probes

Clinical Chemistry

Volumn 63, Issue 2, 2017, Pages 503-512

  Neveling, Kornelia ^a   Mensenkamp, Arjen R ^a   Derks, Ronny ^a   Kwint, Michael ^a   Ouchene, Hicham ^a   Steehouwer, Marloes ^a   Lier, Bart Van ^a   Bosgoed, Ermanno ^a   Rikken, Alwin ^a   Tychon, Marloes ^a   Zafeiropoulou, Dimitra ^a   Castelein, Steven ^a   Hehir Kwa, Jayne ^a   Thung, Djie Tjwan ^a   Hofste, Tom ^a   Lelieveld, Stefan H ^a   Bertens, Stijn M M ^b   Adan, Ivo B J F ^b   Eijkelenboom, Astrid ^a   Tops, Bastiaan B ^a   Yntema, Helger ^a   Stokowy, Tomasz ^c   Knappskog, Per M ^c   Høberg Vetti, Hildegunn ^c   Steen, Vidar M ^c,d   Boyle, Evan ^e   Martin, Beth ^e   Ligtenberg, Marjolijn J L ^a   Shendure, Jay ^e   Nelen, Marcel R ^a   Hoischen, Alexander ^a,f   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF WASHINGTON   (United States)

^f RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; GENOMIC DNA; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; DNA PROBE;

ALLELE; ARTICLE; BREAST CANCER; CONSENSUS; CONTROLLED STUDY; COPY NUMBER VARIATION; DENATURING GRADIENT GEL ELECTROPHORESIS; EXON; GENETIC SCREENING; HUMAN; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; SANGER SEQUENCING; SEMICONDUCTOR; SENSITIVITY AND SPECIFICITY; SINGLE MOLECULE MOLECULAR INVERSION PROBE; SINGLE NUCLEOTIDE POLYMORPHISM; TURNAROUND TIME; WORKFLOW; DNA PROBE; GENETICS; HIGH THROUGHPUT SEQUENCING;

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA COPY NUMBER VARIATIONS; DNA PROBES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS;

EID: 85011585214     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.263897     Document Type: Article

References (41)

1. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med 2012;4:154ra35.
2. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-6.
3. Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8.
4. Nilsson M, Malmgren H, Samiotaki M, Kwiatkowski M, Chowdhary BP, Landegren U. Padlock probes: circularizing oligonucleotides for localized DNA detection. Science 1994;265:2085-8.
5. Hardenbol P, Baner J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003;21:673-8.
6. Porreca GJ, Zhang K, Li JB, Xie B, Austin D, Vassallo SL, et al. Multiplex amplification of large sets ofhumanexons. Nat Methods 2007;4:931-6.
7. Turner EH, Lee C, Ng SB, Nickerson DA, Shendure J. Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods 2009;6: 315-6.
8. O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012;338:1619-22.
9. Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res 2013;23:843-54.
10. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091-2.
11. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-75.
12. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010; 7:708-17.
13. Wevers MR, Hahn DE, Verhoef S, Bolhaar MD, Ausems MG, Aaronson NK, Bleiker EM. Breast cancer genetic counseling after diagnosis but before treatment: A pilot study on treatment consequences and psychological impact. Patient Educ Couns 2012;89:89-95.
14. Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, et al. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat [Epub ahead of print 2016 Oct 21].
15. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triplenegative breast cancer. J Canc Res Clin Oncol 2015; 141:2005-12.
16. Bu R, Siraj AK, Al-Obaisi KA, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer 2016; 139:1091-7.
17. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010;107:12629-33.
18. De Leeneer K, Hellemans J, De Schrijver J, Baetens M, Poppe B, Van Criekinge W, et al. Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Hum Mutat 2011;32:335-44.
19. Michils G, Hollants S, Dehaspe L, Van Houdt J, Bidet Y, Uhrhammer N, et al. Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J Mol Diagn 2012; 14:623-30.
20. Costa JL, Sousa S, Justino A, Kay T, Fernandes S, Cirnes L, et al. Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat 2013;34:629-35.
21. Boyle EA, O'Roak BJ, Martin BK, Kumar A, Shendure J. MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing. Bioinformatics 2014;30:2670-2.
22. Diekstra A, Bosgoed E, Rikken A, van Lier B, Kamsteeg EJ, Tychon M, et al. Translating sanger-based routine DNAdiagnostics into generic massive parallel ion semiconductor sequencing. Clin Chem 2015;61:154-62.
23. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv:13033997 2013.
24. D'Argenio V, Esposito MV, Telese A, Precone V, Starnone F, Nunziato M, et al. The molecular analysis of BRCA1 and BRCA2: next-generation sequencing supersedes conventional approaches. Clin Chim Acta 2015; 446:221-5.
25. De Leeneer K, Hellemans J, Steyaert W, Lefever S, Vereecke I, Debals E, et al. Flexible, scalable, and efficient targeted resequencing on a benchtop sequencer for variant detection in clinical practice. Hum Mutat 2015; 36:379-87.
26. Beck TF, Mullikin JC, Program NCS, Biesecker LG. Systematic evaluation of Sanger validation of nextgeneration sequencing variants. Clin Chem 2016;62: 647-54.
27. Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, et al. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn 2012;14:467-75.
28. Hernan I, Borras E, de Sousa Dias M, Gamundi MJ, Mane B, Llort G, et al. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing. J Mol Diagn 2012;14: 286-93.
29. De Leeneer K, De Schrijver J, Clement L, Baetens M, Lefever S, De Keulenaer S, et al. Practical tools to implement massive parallel pyrosequencing of PCR products in next generation molecular diagnostics. PLoS One 2011;6:e25531.
30. Feliubadalo L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, Tornero E, et al. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet 2013;21:864-70.
31. Ruiz A, Llort G, Yague C, Baena N, Vinas M, Torra M, et al. Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing. Biomed Res Int 2014;2014:542541.
32. Ermolenko NA, Boyarskikh UA, Kechin AA, Mazitova AM, Khrapov EA, Petrova VD, et al. Massive parallel sequencing for diagnostic genetic testing of BRCA genes-a single center experience. Asian Pac J Cancer Prev 2015;16:7935-41.
33. Freedman R, Mountain H, Karina D, Schofield L. A retrospective exploration of the impact of the 'Angelina Jolie Effect' on the Single State-Wide Familial Cancer Program in Perth, Western Australia. J Genet Couns [Epub ahead of print 2016 Jun 6].
34. Pilato B, Pinto R, DeSummaS, Petriella D, Lacalamita R, Danza K, et al. BRCA1-2 diagnostic workflow from NGS to variant identification and final report. Genes Chromosomes Cancer 2016;55:803-13.
35. Umbarger MA, Kennedy CJ, Saunders P, Breton B, Chennagiri N, Emhoff J, et al. Next-generation carrier screening. Genet Med 2014;16:132-40.
36. Kumar A, Boyle EA, Tokita M, Mikheev AM, Sanger MC, Girard E, et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol 2014; 15:530.
37. Ockeloen CW, Khandelwal KD, Dreesen K, Ludwig KU, Sullivan R, van Rooij IA, et al. Novel mutations in LRP6 highlight the role of WNT signaling in tooth agenesis. Genet Med 2016;18:1158-62.
38. de Voer RM, Hahn MM, Mensenkamp AR, Hoischen A, Gilissen C, Henkes A, et al. Deleterious germline BLM mutations and the risk for early-onset colorectal cancer. Sci Rep 2015;5:14060.
39. Eijkelenboom A, Kamping EJ, Kastner-van Raaij AW, Hendriks-Cornelissen SJ, Neveling K, Kuiper RP, et al. Reliable next-generation sequencing of formalin-fixed, paraffin-embedded tissue using single molecule tags. J Mol Diagn 2016;18:851-63.
40. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A 2014;111: 14205-10.
41. Levy-Lahad E, Lahad A, King MC. Precision medicine meets public health: population screening for BRCA1 and BRCA2. J Natl Cancer Inst 2015;107:420.